Health Tech, Health IT

General Catalyst leads $101M investment in startup helping pharma build digital health tools

BrightInsight, a startup developing infrastructure to make it easier for companies to make their own health apps, raised $101 million in  funding. General Catalyst led the series C round.

BrightInsight’s co-founders, from left to right: Vice President of Engineering and Data Science Ben Lee, CTO Ferry Tamtoro, CEO Dr. Kal Patel. Photo credit: BrightInsight

Developing a digital health platform can be a time consuming process. BrightInsight, a San Jose-based startup, does some of the heavy lifting by pulling in data from connected medical devices and drug delivery platforms, and ensuring companies meet security and privacy regulations. It recently raised $101 million in a series C round led by General Catalyst. 

“We believe Brightinsight can redefine biopharma and medtech’s approach to regulated digital health by providing the underlying platform technology to build and scale their programs,” General Catalyst Managing Director Hemant Taneja said in a news release. “Kal and the leadership team are addressing a pressing need and delivering a real benefit: allowing their customers to bring transformative digital health solutions to market more quickly and seamlessly.”

The startup was spun out of contract manufacturer Flex in 2017 by Dr. Kal Patel, the former chief commercial officer of Doctor on Demand. So far, it has launched three digital health products in the last year, including a program with AstraZeneca in the chronic disease management space, a high-risk class C software-as-a-medical device algorithm, and a program with CSL Behring to help patients manage rare immunology, hematology and respiratory conditions.

It also has existing partnerships with Novo Nordisk and Roche. 

To date, BrightInsight has raised $166 million. It plans to use the funds to expand its team and make its platform available in other markets across the Americas and Asia, including China. 

“This financing led by General Catalyst not only validates the market need for a global digital health platform for biopharma and medtech, but it also reinforces the tremendous progress we have made in the past year,” Patel, the company’s CEO, said in a news release. 

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

Taneja, who co-founded Livongo, will serve as a close advisor to the company. Tendo Systems CEO Dan Goldsmith will also join BrightInsight’s board of directors after serving as an advisor.